DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Bayrab (Rabies Immune Globulin) - Published Studies

 
 



Bayrab Related Published Studies

Well-designed clinical trials related to Bayrab (Rabies Immune Globulin)

Safety and immunogenicity of two freeze-dried Vero cell rabies vaccines for human use in post-exposure prophylaxis. [2011.03.24]

Safety and efficacy of novel dermal and epidermal microneedle delivery systems for rabies vaccination in healthy adults. [2010.08.16]

Equivalence between pre-exposure schemes for human rabies and evaluation of the need for serological monitoring. [2010.06]

Immunogenicity and safety study of Indirab: a Vero cell based chromatographically purified human rabies vaccine. [2010.05.28]

A comparative study on the safety and immunogenicity of Purified duck embryo vaccine [corrected] (PDEV, Vaxirab) with purified chick embryo cell vaccine (PCEC, Rabipur) and purifed vero cell rabies vaccine (PVRV, Verorab). [2009.12.10]

[Safety and immunogenicity of rabies vaccine (chick embryo cell) for human use produced in Germany and India] [2009.10]

[Safety and immunogenicity of rabies vaccine (chick embryo cell) for human use produced in Germany and India]. [2009.10]

A three-year clinical study on immunogenicity, safety, and booster response of purified chick embryo cell rabies vaccine administered intramuscularly or intradermally to 12- to 18-month-old Thai children, concomitantly with Japanese encephalitis vaccine. [2009.04]

Comparison of antibody responses after vaccination with two inactivated rabies vaccines. [2009.01.13]

Efficiency of Matricaria chamomilla CH12 and number of doses of rabies vaccine on the humoral immune response in cattle. [2008.12]

First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. [2008.11.05]

Protecting Indian schoolchildren against rabies: pre-exposure vaccination with purified chick embryo cell vaccine (PCECV) or purified verocell rabies vaccine (PVRV). [2008.09]

Intradermal DNA vaccination in ear pinnae is an efficient route to protect cats against rabies virus. [2008.03]

BHK-21 cell culture rabies vaccine: immunogenicity of a candidate vaccine for humans. [2008]

One or three intradermal injections within one week for rabies pre-exposure immunization. [2008]

Immunogenicity and safety of a new Vero cell rabies vaccine produced using serum-free medium. [2007.11.23]

Immunogenicity study of abbreviated rabies preexposure vaccination schedules. [2007.05]

Rabies post-exposure prophylaxis vaccination with purified chick embryo cell vaccine (PCECV) and purified Vero cell rabies vaccine (PVRV) in a four-site intradermal schedule (4-0-2-0-1-1): an immunogenic, cost-effective and practical regimen. [2006.05.08]

Potency requirements of rabies vaccines administered intradermally using the Thai Red Cross regimen: investigation of the immunogenicity of serially diluted purified chick embryo cell rabies vaccine. [2005.06.10]

Safety and immunogenicity of a new chromatographically purified rabies vaccine in comparison to the human diploid cell vaccine. [2004.07]

Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein. [2004.04.01]

[Immune response of suckling mouse brain (CRL) rabies vaccine and tissue culture rabies vaccine (Verorab) in pre-exposure prophylaxis in humans] [2004.01]

Immunogenicity and efficacy of Fermi-type nerve tissue rabies vaccine in mice and in humans undergoing post-exposure prophylaxis for rabies in Ethiopia. [2001.10]

Immunogenicity, safety and lot consistency in adults of a chromatographically purified Vero-cell rabies vaccine: a randomized, double-blind trial with human diploid cell rabies vaccine. [2001.09.14]

The role of vitamin A in enhancing humoral immunity produced by antirabies vaccine. [2001.07]

Immunogenicity and effectiveness of post-exposure rabies prophylaxis with a new chromatographically purified Vero-cell rabies vaccine (CPRV): a two-stage randomised clinical trial in the Philippines. [2000.02.25]

Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine. [2000]

Immunogenicity of rabies postexposure booster injections in subjects who had previously received intradermal preexposure vaccination. [1999.12]

An experimental study on the endurance of immunologic memory of intradermal micro-injection with rabies vaccine and boosting immune effect. [1999.08]

A new Vero cell rabies vaccine: results of a comparative trial with human diploid cell rabies vaccine in children. [1999.07]

Immunogenicity and safety of low-dose intradermal rabies vaccination given during an Expanded Programme on immunization session in Viet Nam: results of a comparative randomized trial. [1999.03]

Persistence of antibodies in children after intradermal or intramuscular administration of preexposure primary and booster immunizations with purified Vero cell rabies vaccine. [1998.11]

Safety and efficacy of purified Vero cell rabies vaccine given intramuscularly and intradermally. (Results of a prospective randomized trial). [1998.10]

Evaluation of the safety, immunogenicity, and pharmacokinetic profile of a new, highly purified, heat-treated equine rabies immunoglobulin, administered either alone or in association with a purified, Vero-cell rabies vaccine. [1998.07.30]

Evaluation of the safety and immunogenicity of a new, heat-treated human rabies immune globulin using a sham, post-exposure prophylaxis of rabies. [1998.03]

Randomised feasibility trial of pre-exposure rabies vaccination with DTP-IPV in infants. [1997.06.07]

Persistence of humoral immunity to rabies 1100 days after immunization and effect of a single booster dose of rabies vaccine. [1997.04]

[Serological effect after immunization with rabies vaccine of different doses] [1996.06]

A simplified and economical intradermal regimen of purified chick embryo cell rabies vaccine for postexposure prophylaxis. [1994.05]

[Pre-exposure rabies immunization in occupational exposed milieu. A 5-year prospective and comparative study of immunogenicity] [1993.04.03]

Intradermal simulated rabies postexposure prophylaxis using purified chick embryo rabies vaccine. [1992.11]

Immunisation with canarypox virus expressing rabies glycoprotein. [1992.06.13]

[Comparison of PVRV and HDCV rabies vaccines as to immunity, reliability and protective value] [1992.01]

What happens if intradermal injections of rabies vaccine are partially or entirely injected subcutaneously? [1990]

Two-year comparative trial on the immunogenicity and adverse effects of purified chick embryo cell rabies vaccine for pre-exposure immunization. [1989.10]

Human diploid cell rabies vaccine purified by zonal centrifugation: a controlled study of antibody response and side effects following primary and booster pre-exposure immunizations. [1989.10]

Immunoenhancement with combined rabies and aluminium-adjuvanted tetanus vaccines. [1989.06]

Comparative study of two human diploid rabies vaccines administered with antirabies globulin. [1988.12]

Interaction of rabies vaccine with human rabies immunoglobulin and reliability of a 2-1-1 schedule application for postexposure treatment. [1988.06]

Dose-response effects in immunizations with keyhole limpet haemocyanin and rabies vaccine: shift in some immunodeficiency states. [1987.11]

Pre-exposure studies with purified chick embryo cell culture rabies vaccine and human diploid cell vaccine: serological and clinical responses in man. [1987.09]

Well-designed clinical trials possibly related to Bayrab (Rabies Immune Globulin)

A field trial to assess a blood-stage malaria vaccine. [2011.09.15]

Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. [2011.02]

A field trial to assess a blood-stage malaria vaccine. [2011]

Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambarene, Gabon. [2010.09.24]

Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial. [2010.02.04]

Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial. [2010]

Five-year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia. [2009.04]

Cell-mediated immunity elicited by the blood stage malaria vaccine apical membrane antigen 1 in Malian adults: results of a Phase I randomized trial. [2009.03.26]

Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. [2009]

Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. [2008.12.11]

Safety and Immunogenicity of an AMA-1 Malaria Vaccine in Malian Adults: Results of a Phase 1 Randomized Controlled Trial. [2008.01.23]

A comparative study on the immunogenicity, safety and tolerance of purified duck embryo vaccine (PDEV) manufactured in India (Vaxirab) and Switzerland (Lyssavac-N): a randomized simulated post-exposure study in healthy volunteers. [2007.12.05]

Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya. [2007.01.02]

Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. [2004.02]

Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study. [2003.03.15]

Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. [2001.12.08]

Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. [1998.05]

The effect of chloroquine prophylaxis on yellow fever vaccine antibody response: comparison of plaque reduction neutralization test and enzyme-linked immunosorbent assay. [1991.01]

Other research related to Bayrab (Rabies Immune Globulin)

Safety and Immunogenicity of purified chick embryo cell rabies vaccine (VaxiRab N) administered intradermally as post exposure prophylaxis. [2014]

Making rabies prophylaxis more economical: immunogenicity and safety results from a preliminary study using a 2-1 intramuscular regimen in healthy volunteers. [2014]

Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. [2011.10]

Evaluation of water-in-oil-in-water multiple emulsion and microemulsion as potential adjuvants for immunization with rabies antigen. [2011.08.17]

Newcastle disease virus-vectored rabies vaccine is safe, highly immunogenic, and provides long-lasting protection in dogs and cats. [2011.08]

Rabies postexposure prophylaxis in a UK travel clinic: ten years' experience. [2011.07]

Immunization of mice with the non-toxic HC50 domain of botulinum neurotoxin presented by rabies virus particles induces a strong immune response affording protection against high-dose botulinum neurotoxin challenge. [2011.06.20]

Live attenuated rabies virus co-infected with street rabies virus protects animals against rabies. [2011.06.06]

Antibody persistence, 32 years after post-exposure prophylaxis with human diploid cell rabies vaccine (HDCV). [2011.05.12]

Characterization of a human antibody fragment Fab and its calcium phosphate nanoparticles that inhibit rabies virus infection with vaccine. [2011.05.09]

Construction and immunogenicity of a recombinant pseudotype baculovirus expressing the glycoprotein of rabies virus in mice. [2011.05]

Rabbit anti-rabies immunoglobulins production and evaluation. [2011.04]

High-density baiting with ONRAB(R) rabies vaccine baits to control Arctic-variant rabies in striped skunks in Ontario, Canada. [2011.04]

Is the skin sensitivity test required for administering equine rabies immunoglobulin? [2011.03]

Generation and characterization of the human neutralizing antibody fragment Fab091 against rabies virus. [2011.03]

Five-year (January 2004-December 2008) surveillance on animal bite and rabies vaccine utilization in the Infectious Disease Hospital, Dhaka, Bangladesh. [2011.01.29]

Immunogenicity and efficacy of two rabies vaccines in wild-caught, captive raccoons. [2011.01]

Analysis of an outbreak of human rabies in 2009 in Hanzhong District, Shaanxi province, China. [2011.01]

Rabies research in resource-poor countries. [2011]

Design of future rabies biologics and antiviral drugs. [2011]

Postexposure prophylaxis for rabies in resource-limited/poor countries. [2011]

Safety and immunogenicity of two freeze-dried Vero cell rabies vaccines for human use in post-exposure prophylaxis. [2011]

Rabies in the Eastern Cape Province of South Africa--where are we going wrong? [2010.12]

Intracerebral vaccination suppresses the spread of rabies virus in the mouse brain. [2010.12]

Socioeconomic status is a critical risk factor for human rabies post-exposure prophylaxis. [2010.10.04]

Seroconversion following incomplete human rabies postexposure prophylaxis. [2010.09.07]

Expression of MIP-1alpha (CCL3) by a recombinant rabies virus enhances its immunogenicity by inducing innate immunity and recruiting dendritic cells and B cells. [2010.09]

Impact of emergency oral rabies vaccination of foxes in northeastern Italy, 28 December 2009-20 January 2010: preliminary evaluation. [2010.07.15]

Incidence of dog bite and anti-rabies vaccine utilization in the, University of Benin Teaching Hospital, Benin City, Nigeria: A 12-year assessment. [2010.07.05]

Evaluation of a commercial rabies ELISA as a replacement for serum neutralization assays as part of the pet travel scheme and oral vaccination campaigns of foxes. [2010.07]

Assessing the relationship between antigenicity and immunogenicity of human rabies vaccines when administered by intradermal route: results of a metaanalysis. [2010.07]

Importance of antirabies revaccination for an adequate antirabies protection in bovine newborns. [2010.07]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017